As per the new agreement, ValiRx will benefit from Physiomics’ expertise in modelling the prostate cancer treatment effects. Credit: Ernesto Eslava from Pixabay.

UK-based oncology consultancy company Physiomics has signed a new agreement with clinical stage drug development company ValiRx.

Physiomics noted that it supersedes the agreement that was signed between the companies in September 2011 to develop and accelerate the progress of ValiRx’s VAL201 anti-cancer compound.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

As per the new agreement, ValiRx will benefit from Physiomics’ expertise in modelling the prostate cancer treatment effects.

It will also use Physiomics’ latest version of Virtual Tumour technology, which will be applied to get valuable information from the additional data generated by the VAL201 clinical trial.

ValiRx CEO Dr Suzy Dilly said: “Enhancing the scientific understanding of our results using cutting edge technology ensures we maximise the value of the data we have collected.

“This will help in the design and execution of future clinical trials and support discussions with potential new partners. We expect that outputs from the application of Physiomics’ technology will be incorporated into scientific publications presenting the results from the VAL201 clinical trial.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Physiomics said it will also support ValiRx in modelling the VAL201 peptide use in endometriosis (VAL301) and Coronavirus (BC201).

So as to model the activity of a drug candidate, Physiomics ‘developed a quantitative systems pharmacology approach’ which uses clinical and pre-clinical data.

This data is used to explore the mechanism of action, impact of the disease as well as optimal dosing strategies.

Physiomics CEO Jim Millen said: “We are delighted to be working once again with ValiRx on a programme of work that replaces and extends that originally agreed in 2011.

“Since the time of the original agreement, Physiomics has gained significant additional experience in the modelling of prostate and other cancers and we will be aiming to generate new insights which can improve development outcomes.”

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact